New inhaled drug for lung disease enters early safety testing

NCT ID NCT06166056

Recruiting now Symptom relief Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety of an inhaled study drug called CHF6333. It involves 45 participants: first, healthy volunteers and people with bronchiectasis receive a single dose; then, people with bronchiectasis receive repeated doses. The goal is to check for side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIECTASIS

Contacts and locations

Locations

Glasgow Royal Infirmary
RECRUITING

Glasgow, United Kingdom
Manchester University NHS Foundation Trust
RECRUITING

Manchester, United Kingdom
Medicines Evaluation Unit (MEU)
RECRUITING

Manchester, United Kingdom
NHS Lothian
RECRUITING

Edinburgh, United Kingdom
Royal Bromptom Hospital (NHS Guy's and Thomas')
RECRUITING

London, United Kingdom
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection
RECRUITING

Cambridge, United Kingdom
Tayside Medical Science Centre, Ninewells Hospital & Medical School
RECRUITING

Dundee, United Kingdom
The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital
WITHDRAWN

Leeds, United Kingdom
University Hospital Southampton NHS Foundation Trust
RECRUITING

Southampton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.